相关实验视频
Updated: May 24, 2025

11:10
Isolation of Human Islets from Partially Pancreatectomized Patients
Published on: July 30, 2011
16.0K
与肉瘤相关的非岛屿细胞瘤低血糖症 (NICTH),病例报告
Atefeh Jannatalipour1,2, Nekoo Panahi3,4, Mahnaz Pejman Sani5,6
1Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
BMC endocrine disorders
|March 5, 2025
概括
非岛屿细胞瘤低血糖症 (NICTH) 是一种罕见的疾病. 这项案例研究表明,复合人体生长激素 (rhGH) 和血管栓塞在患有骨盆肉瘤的患者中有效控制了严重的低血糖症.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 代谢综合征 代谢综合征
背景情况:
- 非岛屿细胞瘤低血糖症 (NICTH) 是一种罕见的副瘤综合征.
- 它的特点是瘤过度分泌高分子量胰岛素样生长因子II (IGF-II).
- 介质细胞和上皮细胞起源的瘤通常涉及.
研究的目的:
- 在患有骨盆肉瘤的患者中报告一个NICTH病例.
- 评估NICTH中严重低血糖症的管理策略.
- 突出重组人体生长激素 (rhGH) 和血管栓塞的作用.
主要方法:
- 一名71岁的男性患有骨盆肉瘤,呈现出严重的低血糖和神经糖症状.
- 通过生物化学分析证实了诊断,显示低胰岛素低血糖症,低C和IGF-1.
- 治疗包括注射乳糖,葡萄糖皮质类药物,rhGH疗法和血管栓塞.
主要成果:
- 最初使用德克斯特和葡萄糖皮质激素的治疗不足.
- 再组合人体生长激素 (rhGH) 治疗减少了对乳糖的需求.
- 瘤的血管栓塞导致血糖稳定和停止使用右糖.
结论:
- 复合人体生长激素 (rhGH) 在减少NICTH中对乳糖的依赖方面至关重要.
- 血管栓塞是NICTH的有效治疗方法,特别是当手术不可行时.
- 这一案例强调了一种多式联络方法来管理复杂的NICTH案例.
相关概念视频
Hypoglycemia and Glucagon
148
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
148
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.0K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.0K
Oral Hypoglycemic Agents: Glinides
127
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
127
Oral Hypoglycemic Agents: Biguanides and Glitazones
149
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
149
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K

